This site is intended for health professionals only
Friday 24 February 2017
Share |

New study provides insights into potential treatment of severe pain in Parkinson’s disease

A study published in The Lancet Neurology has provided important insights into the analgesic effects of prolonged release oxycodone/naloxone (OXN PR) for Parkinson’s disease patients with chronic, severe pain. (1) The primary endpoint of improved average 24-hour pain score with OXN PR versus placebo at week 16 was not met (p=0.058), however assessments at other time points as well as secondary endpoint data indicate some potentially positive treatment effects with OXN PR. (1)
 

Ads by Google